Establishment Labs Holdings Inc. (ESTA)

NCM – Цена в реальном времени. Валюта: USD

88.38

-0.69 (-0.77%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

88.00

-0.38 (-0.43%)

После закрытия: Jun 26, 2026, 5:35 PM EDT

18.05.2026

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. “Route 92 Medical has built a strong position in neurovascular intervention,” said Raj Denhoy, CFO at Route 92 Medical.

06.05.2026

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

06.05.2026

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.

06.05.2026

Establishment Labs Reports First Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United State.

04.05.2026

Weight-loss revolution sparks new appetite for aesthetics firms

Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quarter earnings this week.

30.04.2026

Establishment Labs® Refinances Credit Facility

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The amended and restated facility refinances the company's existing debt and allows access to additional capital to support ongoi.

23.04.2026

Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Cana.

Видео

No Data

There is no data to display

Establishment Labs® Refinances Credit Facility

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The amended and restated facility refinances the company's existing debt and allows access to additional capital to support ongoi.

07.04.2026

Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction.

Establishment Labs Holdings Inc. (ESTA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Establishment Labs Holdings Inc. (ESTA)

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Reports First Quarter 2026 Financial Results

Weight-loss revolution sparks new appetite for aesthetics firms

Establishment Labs® Refinances Credit Facility

Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

Видео

No Data

Пресс-релизы

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Reports First Quarter 2026 Financial Results

Establishment Labs® Refinances Credit Facility

Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Reports First Quarter 2026 Financial Results

Weight-loss revolution sparks new appetite for aesthetics firms

Establishment Labs® Refinances Credit Facility

Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

Видео

No Data

Пресс-релизы

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Reports First Quarter 2026 Financial Results

Establishment Labs® Refinances Credit Facility

Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market

Search stocks

Establishment Labs Holdings Inc. (ESTA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Establishment Labs Holdings Inc. (ESTA)

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Reports First Quarter 2026 Financial Results

Weight-loss revolution sparks new appetite for aesthetics firms

Establishment Labs® Refinances Credit Facility

Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

Видео

No Data

Пресс-релизы

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Reports First Quarter 2026 Financial Results

Establishment Labs® Refinances Credit Facility

Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Reports First Quarter 2026 Financial Results

Weight-loss revolution sparks new appetite for aesthetics firms

Establishment Labs® Refinances Credit Facility

Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

Видео

No Data

Пресс-релизы

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Establishment Labs Reports First Quarter 2026 Financial Results

Establishment Labs® Refinances Credit Facility

Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market